We have also analyzed and compared the expression of thioredoxin in CD138+ myeloma cells from newly diagnosed myeloma patients, myeloma patients that were treated with bortezomib containing regimen, and relapsed/refractory myeloma patients who had prior exposure to bortezomib (Fig. 7). The gene discussed is SDC1; the disease is plasma cell myeloma.